جست‌وجوی استاد و پژوهشگر

Andre Levchenkoمشاهده پروفایل

استاد

• Systems Biology
• Signal Transduction
• Cell Communication
• +۵ مورد دیگر

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

Sachdev Sidhuمشاهده پروفایل

استاد پژوهشی

• Synthetic Antibodies
• Protein Engineering
• Biotechnology
• +۵ مورد دیگر

Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.

Dan A. Dixonمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Oncology
• RNA Biology
• +۳ مورد دیگر

Dan A. Dixon is a Professor and Associate Director of Community Outreach and Engagement at the Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences (UAMS), where his research focuses on post-transcriptional gene regulation mechanisms in cancer pathogenesis. His academic credentials include: Ph.D. from Northwestern University B.A. from Augustana University Dr. Dixon's research centers on RNA-binding proteins (notably HuR and tristetraprolin) and their role in destabilizing oncogenic mRNA networks. His laboratory investigates how dysregulation of these post-transcriptional controllers permits overexpression of tumor-promoting genes involved in proliferation, angiogenesis, and metastasis. Key focus areas include colorectal cancer mechanisms, autophagy regulation via Rab27B, stress granule dynamics in mutant p53 contexts, and extracellular vesicle-mediated tumor microenvironment activation. Analysis of his 2022-2025 publications reveals intensifying work on XPO1 inhibition for colorectal cancer chemoprevention, Rab27B-autophagy axis characterization, and mutant p53 vulnerabilities. His studies consistently employ molecular techniques, mouse models (APC Min/+ ), and translational approaches to identify biomarkers and therapeutic targets. Dr. Dixon maintains active laboratory facilities at WPRCI 947 and 951, directing research that bridges fundamental RNA biology with clinical oncology applications. His leadership in community outreach complements his bench-to-bedside research philosophy.

Nhiem Tranمشاهده پروفایل

مدرس ارشد

• Biomedical Engineering
• Nanotechnology
• Nanomedicine
• +۱۲ مورد دیگر

Dr. Nhiem Tran is a Senior Lecturer in the Department of Applied Chemistry and Environmental Science at RMIT University's School of Science, part of the STEM College. He joined RMIT in 2015 as a Vice Chancellor's Research Fellow after completing his PhD in Physics at Brown University (USA, 2012) and postdoctoral research at Rhode Island Hospital (USA), CSIRO, and the Australian Synchrotron. His research focuses on developing biomaterials for drug delivery, gene therapy, and medical implants, particularly lipid nanoparticles and 3D-printed metallic implants. He leads the Biomaterial Interfaces group, investigating self-assembled lipid nanoparticles for cancer and autoimmune disease treatments. His work has resulted in over 65 high-impact publications and numerous awards, including the RMIT Vice Chancellor's Research Fellowship and the Stein/Bellet Foundation Fellowship. Tran's funding comes from grants such as the ARC Discovery Project, mRNA Victoria, and the CASS Foundation. His research interests span nanomedicine, biomedical engineering, and materials science, with a focus on applications in drug delivery, bacterial infection control, and orthopaedic implants. Education: PhD in Physics (Brown University, 2012) Key Projects: 3D-printed diamond-titanium implants, lipid nanoparticle drug carriers, and antimicrobial coatings. He actively supervises postgraduate research in areas like nanomaterials for drug delivery and biomedical applications.

• Biopharmaceutics
• Drug Targeting
• Nanomedicine
• +۳ مورد دیگر

Prof. Robbert Jan Kok is a Professor of Drug Delivery Technology at Utrecht University's Utrecht Institute for Pharmaceutical Sciences (UIPS) and Programme Director for the Bachelor of Pharmacy. He obtained his Pharmacy degree (1993) and PhD in renal drug targeting (1998) from the University of Groningen, followed by postdoctoral research on endothelial-targeted drug delivery. His work spans curriculum development for pharmacy programs and interdisciplinary research in drug innovation. Research Focus: Kok specializes in advanced drug delivery systems, including nanomedicines for kinase inhibitors, 3D-printed formulations, and stimuli-responsive carriers. Key areas include: Targeted delivery to tumors, kidneys, and inflamed tissues Polymeric micelles, liposomes, and microspheres for sustained release Biopharmaceutics and pharmacokinetic optimization Publication Trends: His recent work emphasizes nanotechnology-enabled therapies (e.g., curcumin nanodelivery, photodynamic micelles) and device-integrated drug release (3D-printed implants, macroencapsulation). Studies frequently combine material science with preclinical validation in cancer, renal diseases, and inflammatory disorders. Academic Leadership: Kok oversees student advising, laboratory operations, and international collaborations at UIPS. His team explores translational applications of drug delivery platforms, including partnerships for vascularized tissue engineering and combination therapies.

Yeonhwa Parkمشاهده پروفایل

استاد

• Functional Foods
• Obesity
• Environmental Contaminants
• +۳ مورد دیگر

Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.

Shutao Maمشاهده پروفایل

استاد

• Medicinal Chemistry
• Antibacterial Drug Discovery
• Antibiotic Resistance
• +۳ مورد دیگر

Shutao Ma is a Professor and Doctoral Supervisor at Shandong University's School of Pharmaceutical Sciences, serving as Director of the Department of Medicinal Chemistry since 2009. He has received the Special Government Allowance from China's State Council since 2002 and the seventh youth award of Shandong province for his contributions to medicinal chemistry. His academic credentials include: Ph.D. in Pharmaceutical Sciences, Shandong University (2004-2007) M.Sc. in Pharmaceutical Sciences, Shandong Medical University (1988-1991) B.Sc. in Pharmaceutical Sciences, Shandong Medical University (1981-1986) Professor Ma's research pioneers innovative strategies against antibiotic-resistant bacteria through three interconnected pillars: 1) Designing FtsZ/AcrB-targeted small molecules to disrupt bacterial cell division and efflux mechanisms; 2) Structural optimization of macrolides, glycopeptides, and lipopeptides to overcome resistance; 3) Total synthesis and mechanistic studies of marine-derived antibacterial natural products. His work bridges synthetic chemistry with microbiological validation to develop next-generation antimicrobials. Analysis of his 15 most recent publications (2014-2016) reveals a dominant focus on antibacterial drug discovery (87% of works), particularly FtsZ inhibitors (33%) and macrolide derivatives (27%). Emerging themes include quorum sensing modulation (7%) and antiviral/anticancer applications (13%), demonstrating strategic expansion while maintaining core expertise in resistance mechanisms. His scientific recognition includes: First prize of Shandong science and technology progress award (2000) Special government allowance from the State Council (2002) The seventh youth awards of Shandong province (2002) As a Doctoral Supervisor, Professor Ma mentors the next generation of medicinal chemists while directing a robust research program funded by 12 major grants. His National Natural Science Foundation portfolio (2004-2020) spans antibacterial discovery, while Shandong Provincial grants (2006-2017) and China-Australia collaborations (2014-2017) support translational development of resistance-breaking agents. Leading the Department of Medicinal Chemistry, he oversees a multidisciplinary team integrating synthetic chemistry, microbiology, and computational modeling to advance antibacterial drug candidates from concept to preclinical validation, with particular emphasis on FtsZ-targeted therapeutics and macrolide engineering.

• Bone Biology
• Cartilage Development
• Transcriptional Regulation
• +۴ مورد دیگر

Amjad Javed is a Professor and Associate Dean at the University of Alabama at Birmingham , with primary appointments in the School of Dentistry - Oral & Maxillofacial Surgery and joint affiliations in Cell, Developmental and Integrative Biology , Otolaryngology , and Biomedical Engineering . His research spans bone biology, cartilage development, and myeloma bone disease. PhD in Physiology (University of the Punjab, 2003) MS in Zoology/Animal Biology (University of the Punjab, 1992) Research Interests focus on transcriptional regulation via RUNX2 and Sp7 in skeletogenesis, vascular calcification mechanisms, epigenetic control of bone formation, and tumor-bone microenvironment interactions in multiple myeloma. Key subfields include endochondral ossification, osteoclast differentiation, and nanomatrix-based tissue engineering. Scientific Contributions include discoveries about RUNX2's role in postnatal bone resorption, λ5 protein's impact on skeletal aging, and heparanase's promotion of myeloma metastasis. His work demonstrates RUNX2's dual function in chondrocyte apoptosis and cartilage degradation. Teaching & Mentorship involves graduate committee service for over 15 students and instruction in courses like Connective Tissue and Bone , Oral & Skeletal Biology , and Journal Clubs . Collaborations span Comprehensive Arthritis, Musculoskeletal, Bone and Autoimmunity Center , Integrative Center for Aging Research , and Biomatrix Eng Regen Med Center .

Tatiana Seguraمشاهده پروفایل

استاد

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۵ مورد دیگر

Tatiana Segura is a Professor of Biomedical Engineering, Neurology, and Dermatology at Duke University's Pratt School of Engineering, where she also serves as Co-director of the Center for Biotechnology and Tissue Engineering and MPI of the T32 Biotechnology Training grant. Her research focuses on designing biomaterials to promote endogenous repair through geometry design and delivery of genes, proteins, and drugs. She has made significant contributions to the development of microporous annealed particle (MAP) hydrogels and other biomaterial systems for tissue regeneration. B.S. in Bioengineering from University of California, Berkeley (1999) Ph.D. in Chemical Engineering from Northwestern University (2004) Professor Segura's research centers on biomaterials engineering for tissue repair and regeneration. Her lab designs innovative biomaterial interventions that promote brain plasticity after stroke, enable scarless healing in skin wounds, induce tolerance of transplanted skin, and promote constructive immune responses after biomaterial implantation. She pioneered the development of microporous annealed particle (MAP) hydrogels that have become widely adopted in regenerative medicine research. Her work uniquely bridges immunology, materials science, and clinical applications to create therapeutic biomaterials that harness the body's own healing capabilities. Her recent publications demonstrate a strong focus on spatial control of biomaterial properties, with emphasis on void space analysis, immune cell recruitment, and vascularization. The research shows a progression from fundamental biomaterial characterization to increasingly sophisticated therapeutic applications, particularly in stroke recovery and wound healing. Her work integrates proteomics, lipidomics, and advanced imaging to understand the molecular mechanisms underlying biomaterial-mediated tissue regeneration. Senior Member of the National Academy of Inventors (2023) Acta Biomaterialia Silver Medal (2021) Clemson Award for Contributions to Literature (2024) 15 d/e Plenary Award from AICHE Food, Pharmaceutical, and Bioengineering Division (2018) Fellow of the American Institute for Medical and Biological Engineers (2016) Professor Segura actively mentors the next generation of scientists, currently supervising 12 graduate students, 4 postdoctoral scholars, 2 master's students, 16 undergraduates, and other trainees. Her laboratory has been continuously funded since 2008 with multiple NIH grants, including her current role as MPI of the T32 Biotechnology Training grant. She has received substantial support from the NSF (including a CAREER award), American Heart Association, and American Society of Gene and Cell Therapy. Her Segura Lab operates as a multidisciplinary team comprising engineers, biologists, and clinicians working together to translate biomaterial discoveries into clinical applications. The lab's 'MAP' technology platform has enabled numerous collaborations across Duke and other institutions, focusing on brain repair after stroke, scarless skin healing, and immune-modulating biomaterials. The lab maintains strong industry partnerships to accelerate the translation of their biomaterial technologies into clinical use.

Barbara L. Hempsteadمشاهده پروفایل

استاد

• Neuroscience
• Neurotrophin Signaling
• Neurodegenerative Diseases
• +۵ مورد دیگر

Dr. Barbara L. Hempstead is a Professor of Neuroscience and Medicine at Weill Cornell Medical College, where she has held positions since 2001 and 2002 respectively. Her research focuses on neurotrophin signaling mechanisms, particularly the roles of BDNF and its receptors in neuroinflammation, synaptic plasticity, and neurodegenerative diseases. She has made significant contributions to understanding proBDNF/proNGF signaling pathways in neuronal apoptosis and vascular biology. Education: M.D., Ph.D., Washington University School of Medicine (1982) B.A., Tufts University (1976) Dr. Hempstead's work bridges molecular neuroscience and cardiovascular biology, with a particular interest in receptor stoichiometry (p75NTR, TrkB), neurotrophin-induced synaptic remodeling, and therapeutic applications of neurotrophin modulators in Huntington's disease and post-seizure neuronal injury. Her lab investigates how genetic variants like BDNF Val66Met influence anxiety-related behaviors, social memory, and neurodegenerative disease progression through altered neurotrophin trafficking and signaling. Her recent publications highlight neuroinflammatory mechanisms (2023), immune-neurotrophin interactions (2022), and molecular pathways involving BDNF prodomain structure (2020) and SorCS2-mediated receptor trafficking (2017-2020). While no scientific awards are explicitly mentioned in the scraped text, her funded research (National Institute on Aging, NIMH) demonstrates sustained recognition of her work in neurotrophin biology. Dr. Hempstead's lab develops in vitro and in vivo models to study neurotrophin-receptor dynamics, including 3D culture systems for angiogenesis research and transgenic mouse models for Huntington's disease. Her interdisciplinary approach combines molecular neurobiology with vascular physiology to uncover novel therapeutic targets for neurological and cardiovascular conditions.

Shyni Vargheseمشاهده پروفایل

استاد

• Tissue Engineering
• Biomaterials
• Regenerative Medicine
• +۵ مورد دیگر

Shyni Varghese is the Laszlo Ormandy Distinguished Professor of Orthopaedic Surgery at Duke University, with joint appointments in Mechanical Engineering & Materials Science and Biomedical Engineering. She directs the Varghese Lab, an interdisciplinary team focused on smart biomaterials, organ-on-chip models, rejuvenation therapies, and translational medical technologies. Her research bridges tissue engineering, regenerative medicine, and disease modeling to address bone healing, osteoarthritis, and age-related tissue degeneration. Education: Ph.D. in Chemistry/Materials Science, National Chemical Laboratory (India), 2002 Research spans four pillars: Smart Biomaterials : Engineered ECM mimetics, self-healing hydrogels, and stimuli-responsive systems for tissue regeneration. Miniature Organs : Organoid and organ-on-chip platforms (e.g., tumor-on-chip, lung alveolus models) to study disease mechanisms. Rejuvenation : Targeting cellular senescence, adenosine signaling, and inflammation to enhance aged tissue repair. Bench to Bedside : Translating technologies like 'bone bandages' and nanocarriers for fracture healing and osteoporosis. Recent publications emphasize orthopaedic repair (fracture healing, osteoarthritis), immunomodulation (macrophage reprogramming, immunotherapy), and advanced biomaterials (self-healing lubricants, cartilage-penetrating carriers). Studies frequently employ mouse models and microengineered platforms to dissect pain mechanisms, senescence, and tissue regeneration pathways. Dr. Varghese advises 10+ doctoral students and postdoctoral researchers. Her lab has pioneered innovations like 'DraBot' (environment-responsive soft robot) and 'cell pouch' xenotransplantation devices. Collaborative projects include NIH-funded work on bone radioprotection and NSF-supported biomaterial design. The Varghese Lab occupies the Duke Medical Science Research Building, fostering collaborations with clinicians and engineers. Current projects explore: Senolysis for neuroinflammation mitigation Adenosine-based therapies for bone loss 3D tumor models for immunotherapy screening

James Lacefieldمشاهده پروفایل

استاد

• Biomedical Ultrasound Imaging
• Vascular Imaging
• Cancer Research Applications
• +۵ مورد دیگر

James Lacefield is a Professor in both the Department of Electrical and Computer Engineering and the Department of Medical Biophysics at Western University. He serves as Director of the School of Biomedical Engineering and maintains his research laboratory in the Amit Chakma Engineering Building. His academic appointments span multiple disciplines, reflecting the interdisciplinary nature of his work in biomedical ultrasound imaging. Dr. Lacefield earned his Ph.D. and B.S.E. in Biomedical Engineering from Duke University. His educational background established the foundation for his current research program that bridges engineering principles with medical applications. His research focuses on the physical acoustics and signal processing aspects of ultrasound imaging, with particular emphasis on quantitative vascular imaging applications. Dr. Lacefield's laboratory develops novel methods for color Doppler, power Doppler, and contrast-enhanced ultrasound imaging, with primary applications in cancer research. Current projects include optimization of high-resolution ultrasound systems for tumor vascular characterization and development of methods to quantify spatial blood flow distribution in tumors. Analysis of his recent publications reveals a strong focus on quantitative ultrasound techniques for cancer applications, with particular attention to tumor perfusion assessment using contrast-enhanced ultrasound. His work demonstrates increasing sophistication in speckle analysis methods to improve the reliability of perfusion measurements in preclinical tumor models. Associate Editor, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control Member, Council of Chairs of Bioengineering and Biomedical Engineering Member, College of Reviewers, Canadian Institutes of Health Research Dr. Lacefield maintains active collaborations with multiple research groups including the Imaging Research Laboratories at Robarts Research Institute. His professional activities include editorial work for major ultrasound journals and participation in national review panels for biomedical research funding.

Kibret Mequanintمشاهده پروفایل

استاد

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۶ مورد دیگر

Dr. Kibret Mequanint is a full Professor at Western University's Department of Chemical and Biochemical Engineering, with cross-appointments in Biomedical Engineering. Holding a PhD from University of Stellenbosch and postdoctoral experience at Technical University of Darmstadt and McMaster University, his research bridges polymer science, materials engineering, and life sciences with applications in Biomaterials , Tissue Engineering , and Regenerative Medicine . His work spans both fundamental and translational research in cell-material interactions , polymer biomaterial design , and therapeutic radiation dosimeters , with technologies transferred to commercial applications. Leading scholar and educator with awards from NSERC, CIHR, and Western University Fellow of: American Institute for Medical and Biological Engineering (AIMBE), Ethiopian Academy of Sciences, International Union of Societies for Biomaterials Science and Engineering, Canadian Academy of Engineering Extensive editorial and panel service for NSERC, CIHR, and international journals His research program has produced over 170 refereed publications, focusing on conductive hydrogels , bioadhesives , and vascular tissue engineering . Recent work on endoscopy-deliverable bioadhesives and snake venom-derived hemostatic gels has attracted global media attention. He has served in leadership roles at the Canadian Biomaterials Society and university governance bodies including Senate and Board of Governors.

Nadya Dimitrovaمشاهده پروفایل

استادیار

• Long Non-Coding RNAs
• Cancer Biology
• Molecular Biology
• +۳ مورد دیگر

Nadya Dimitrova is an Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale University, affiliated with the Yale School of Medicine. She holds secondary appointments in Genetics and is a member of multiple interdisciplinary centers, including the Center for RNA Science and Medicine. Her research focuses on long non-coding RNAs (lncRNAs) and their roles in cancer biology, particularly in tumor suppression and oncogenesis. Dimitrova earned her Sc.B. in Biochemistry from Brown University (2002), a Ph.D. from The Rockefeller University (2009), and completed postdoctoral training at MIT's Koch Institute. Notable awards include the HHMI Predoctoral Fellowship, Damon Runyon Postdoctoral Fellowship, and the 2023 Yale Cancer Center Class of '61 Award. Her lab explores lncRNA mechanisms using genomic and genetic tools, aiming to uncover their roles in cancer pathways. Recent work highlights lncRNAs' roles in metastasis, cardiac hypertrophy, and p53 signaling. Collaborations with researchers like Antariksh Tyagi and Clara Liao drive translational insights into RNA-based therapies. Education: Sc.B., Brown University (2002); Ph.D., The Rockefeller University (2009). Research interests include lncRNA regulation, cancer transcriptomics, and RNA-driven disease mechanisms. Her lab integrates systems biology approaches to dissect lncRNA functions in health and disease.

• Gynecologic Oncology
• Cancer Immunotherapy
• Tumor Immunology
• +۷ مورد دیگر

Dr. Alessandro D. Santin is a Professor at the Yale School of Medicine within the Department of Obstetrics, Gynecology & Reproductive Sciences . He serves as Clinical Research Team Leader for Gynecologic Oncology at the Yale Cancer Center and co-chief of the Section of Gynecologic Oncology. Graduated magna cum laude from the University of Brescia, Italy Completed fellowships at the University of California, Irvine and University of Arkansas for Medical Sciences Dr. Santin's research bridges tumor immunology and translational oncology, focusing on: Immunotherapy for chemotherapy-resistant gynecologic cancers Therapeutic HPV vaccines for genital tumors Monoclonal antibody development Angiogenesis and radiation biology His recent publications highlight advancements in: VEGF/VEGFR2 system targeting for ovarian cancer Personalized medicine approaches with biomarkers Microsatellite instability in endometrial cancer immunotherapy Antibody-drug conjugates for uterine serous carcinoma NAC supplementation in post-COVID gynecologic patients Scientific Awards: American Association young investigator award Italian Society of Gynecologic Oncologists award for translational science Dr. Santin's lab (Laboratory for Surgery, Obstetrics & Gynecology) at Yale collaborates extensively, with 50+ postdoctoral fellows mentored. Current grants include NIH funding for Clostridium Perfringens Enterotoxin as a novel ovarian cancer therapy and leadership in multiple Gynecologic Oncology Group trials.